Korean investment firm SK Holdings is looking to buy Yposkesi to add a cell and gene therapy business to its growing CDMO portfolio. While the deal is not done and financials have not been revealed, SK Holdings is looking to become the majority shareholder in the majority shareholder of Yposkesi, a France-based contract development and manufacturing organization (CDMO) specializing in advanced therapies. If it goes through, Yposkesi will fall under SK’s CDMO holding company, California-headquartered SK Pharmteco, formed last year to oversee the growing portfolio of pharma manufacturing facilities and businesses. Having first played in the pharma intermediate space, SK Holdings entered the small molecule active pharmaceutical ingredient sector in 2005, expanding the business in 2017 by constructing a facility in Sejong, Korea and buying an Irish facility from Bristol-Myers Squibb. And in 2018, the firm bought fine chemicals firm AMPAC
For further information, see Bioprocess Intl (https://bioprocessintl.com/bioprocess-insider/deal-making/sk-holdings-set-to-jump-into-cell-and-gene-cdmo-space-with-yposkesi-buy/)
